Vivimed Labs Ltd
Vivimed Labs Ltd is primarily engaged in the business of APIs, CDMO, Finished Dosage Formulation, Specialty Chemicals and retail branded formulation manufacturing.[1]
- Market Cap ₹ 41.0 Cr.
- Current Price ₹ 4.95
- High / Low ₹ /
- Stock P/E
- Book Value ₹ 5.50
- Dividend Yield 0.00 %
- ROCE -6.45 %
- ROE -42.6 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.90 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -17.8% over past five years.
- Promoter holding is low: 7.77%
- Company has a low return on equity of -84.0% over last 3 years.
- Contingent liabilities of Rs.183 Cr.
- Company might be capitalizing the interest cost
- Company has high debtors of 161 days.
- Promoter holding has decreased over last 3 years: -13.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 432 | 430 | 319 | 570 | 261 | 252 | 277 | 210 | 218 | 177 | 137 | 104 | 93 | |
| 328 | 323 | 233 | 319 | 183 | 184 | 237 | 182 | 227 | 365 | 170 | 118 | 98 | |
| Operating Profit | 104 | 107 | 86 | 250 | 78 | 67 | 40 | 28 | -9 | -188 | -33 | -15 | -5 |
| OPM % | 24% | 25% | 27% | 44% | 30% | 27% | 14% | 13% | -4% | -106% | -24% | -14% | -5% |
| 2 | 1 | 1 | 9 | 2 | 9 | -0 | 6 | 1 | 0 | 10 | 4 | 5 | |
| Interest | 49 | 64 | 57 | 59 | 53 | 53 | 43 | 42 | 40 | 36 | 2 | 3 | 4 |
| Depreciation | 18 | 21 | 19 | 27 | 18 | 18 | 17 | 16 | 17 | 107 | 18 | 19 | 20 |
| Profit before tax | 39 | 24 | 11 | 173 | 9 | 5 | -21 | -24 | -65 | -330 | -44 | -32 | -24 |
| Tax % | 31% | 22% | 28% | 27% | -12% | -20% | -8% | -1% | 4% | -1% | 0% | 0% | |
| 27 | 19 | 8 | 126 | 10 | 6 | -19 | -23 | -68 | -328 | -44 | -32 | -24 | |
| EPS in Rs | 3.29 | 2.34 | 1.00 | 15.59 | 1.20 | 0.75 | -2.31 | -2.81 | -8.17 | -39.56 | -5.35 | -3.80 | -2.93 |
| Dividend Payout % | 2% | 0% | 0% | 3% | 33% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -18% |
| 3 Years: | -22% |
| TTM: | -22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -25% |
| 5 Years: | -22% |
| 3 Years: | -27% |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | -33% |
| 3 Years: | -84% |
| Last Year: | -43% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 359 | 358 | 353 | 545 | 551 | 556 | 537 | 508 | 441 | 117 | 73 | 42 | 29 |
| 636 | 698 | 599 | 571 | 446 | 348 | 304 | 323 | 357 | 377 | 375 | 375 | 375 | |
| 193 | 231 | 397 | 229 | 243 | 234 | 210 | 247 | 258 | 286 | 217 | 206 | 219 | |
| Total Liabilities | 1,203 | 1,303 | 1,365 | 1,361 | 1,255 | 1,155 | 1,067 | 1,095 | 1,072 | 796 | 681 | 639 | 640 |
| 397 | 377 | 387 | 433 | 405 | 381 | 356 | 416 | 429 | 343 | 326 | 315 | 305 | |
| CWIP | 16 | 63 | 41 | 59 | 43 | 64 | 70 | 58 | 40 | 21 | 21 | 17 | 17 |
| Investments | 228 | 230 | 230 | 88 | 152 | 88 | 88 | 161 | 161 | 161 | 59 | 59 | 59 |
| 563 | 633 | 708 | 781 | 656 | 622 | 554 | 459 | 442 | 271 | 276 | 248 | 259 | |
| Total Assets | 1,203 | 1,303 | 1,365 | 1,361 | 1,255 | 1,155 | 1,067 | 1,095 | 1,072 | 796 | 681 | 639 | 640 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -45 | 41 | -54 | 28 | 207 | 82 | 75 | 180 | 25 | 33 | -97 | 6 | |
| -149 | -50 | -11 | 30 | -38 | 56 | 3 | -138 | -11 | -2 | 100 | -4 | |
| 193 | 9 | 59 | -50 | -175 | -123 | -91 | -46 | -13 | -35 | -6 | -3 | |
| Net Cash Flow | -0 | 1 | -7 | 8 | -6 | 15 | -13 | -5 | 1 | -3 | -2 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 155 | 194 | 264 | 144 | 234 | 148 | 118 | 133 | 106 | 104 | 159 | 161 |
| Inventory Days | 265 | 410 | 744 | 579 | 1,236 | 1,284 | 640 | 954 | 608 | 106 | 340 | 354 |
| Days Payable | 61 | 84 | 68 | 92 | 99 | 160 | 75 | 124 | 95 | 77 | 211 | 211 |
| Cash Conversion Cycle | 359 | 520 | 940 | 632 | 1,371 | 1,271 | 683 | 963 | 619 | 134 | 289 | 304 |
| Working Capital Days | 121 | 132 | 291 | 168 | 345 | 375 | 319 | 213 | 116 | -299 | -311 | -513 |
| ROCE % | 10% | 8% | 7% | 22% | 6% | 6% | 3% | 2% | -3% | -44% | -9% | -6% |
Documents
Announcements
-
Revocation Of Suspension In Trading Of Equity Shares
11 Dec - BSE/NSE revoke Vivimed Labs suspension; trading resumes Dec 18, 2025 (T/Trade-for-Trade).
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
10 Dec - EGM Dec 10, 2025: shareholders approved initiating pre-packaged insolvency process; ~99.70% votes in favour.
- Shareholder Meeting / Postal Ballot-Outcome of EGM 10 Dec
-
Pre Dispatch Of Notice Of EGM Newspaper Add
21 Nov - EGM notice advertisement published Nov 16, 2025; EGM via video conferencing; notice to be dispatched electronically.
-
Post Dispatch Of Notice Of EGM Newspaper Add
21 Nov - Newspaper advertisement for Vivimed Labs' EGM via VC; notice dispatched electronically on Nov 17, 2025; ad published Nov 20.
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Aug 2019TranscriptAI SummaryPPT
-
Mar 2019TranscriptAI SummaryPPT
-
Nov 2018TranscriptAI SummaryPPT
-
Aug 2018TranscriptAI SummaryPPT
-
Jun 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Nov 2017TranscriptAI SummaryPPT
-
Aug 2017Transcript PPT
-
Nov 2016Transcript PPT
-
Aug 2016Transcript PPT
-
May 2016Transcript PPT
-
Aug 2015TranscriptAI SummaryPPT
API Division (~69% of revenues)[1]
This is the flagship division of the company which is primarily managed by its subsidiary UQUIFA s.a. based in Spain. The division further has 2 sub-divisions :-[2]